curves based on tumor resectability. A P value < .05 was considered statistically significant.
| CASE REPORT
A 72-year-old woman with a medical history of arthrosis was admitted to our institution with jaundice. Laboratory testing indicated elevated transaminase levels (Alanine aminotransferase (ALT): 83 UI/L; aspartate aminotransferase (AST): 206 UI/L) and an elevated total bilirubin level (206 µmol/L). The carcinoembryonic antigen level was normal, and the cancer antigen 19-9 level was slightly elevated (51 U/mL). The patient received an abdominal ultrasound and chest plus abdominal computed tomography (CT), which revealed a mass in the head of the pancreas measuring 2.2 × 1.7 cm with biliary and pancreatic ductal dilatation ( Figure 1A ). Positron emission tomography (PET)-CT was used to investigate the origin of this mass, which revealed a unique pancreatic mass with a standardized uptake value of 12.5 ( Figure 1B ). Endoscopic ultrasound-guided fine needle aspiration (FNA) was performed. The histopathology of the biopsy was consistent with SCC. The workup for identifying an alternative primary tumor was negative, including the gynecological, dermatological, "ear, nose, throat" examinations, and endoscopic evaluation of the upper and lower gastrointestinal tracts. A diagnosis of primary SCC of the pancreas was made. Based on the patient's age, performance status, and the nonmetastatic tumor stage, curative therapy was rapidly implemented. The pancreas tumor was treated by "en bloc" resection because it was adherent to transverse colon. We performed a cephalic duodenopancreatectomy (Whipple procedure) and transverse colectomy with manual anastomosis by laparotomy. The definitive histology confirmed the diagnosis of primary pancreatic SCC with perineural neoplastic invasion ( Figure 1C-D) . Based on the tumor-nodemetastasis-resection classification, the tumor was diagnosed as T2N0M0R0. Subsequent to surgery, the patient received chemotherapy using gemcitabine (six cycles). The patient is currently in complete remission after a follow-up interval of 26 months. The nature and objectives of the study were explained to the patient, and informed consent was formally obtained. No reference to the patient's identity was made at any stage during data analysis or in the report.
| DISCUSSION AND LITERATURE REVIEW
The literature search identified 44 eligible articles, written in English, French, German, or Spanish. A total of 52 cases of primary pancreatic SCC were included in the analysis (Table  1) . 1, 4, 9, 10, 11, 21, The median age at diagnosis was 63. Figure  2 ). Three (20%) cases of local recurrence or metastasis were observed in this group after curative treatment ( Figure 2 ).
A total of 11 patients had a locally advanced tumor, and 10 (90%) of these patients received chemo-or radiotherapy ( Table 2 ). The 24 (38.5%) patients with metastasis received palliative care ( Table 2) . The majority of patients with inoperable SCC received gemcitabine and cisplatin, either alone or in combination, as a first-line treatment (Table 1) T A B L E 1 (Continued) the resectable group, compared with 8 months in the locally advanced tumor group and 4 months in the metastasis group (P = .0008; Figure 3 ). Squamous cell carcinoma of the pancreas is exceedingly rare, with an incidence rate of 0.5%-5%. 39 Because of this rarity, it is often presumed to be a result of metastasis from another primary site. 40 The pathogenesis is not well understood, and a number of mechanisms underlying its development have been proposed: malignant transformation of squamous metaplasia of ductal cells, squamous metaplasia in adenocarcinoma, and squamous differentiation with malignant transformation of pluripotent primitive cells. 41 The first case of SCC was described by Lowry in 1949. 42 Since then, only case reports from the literature have been available to guide workup and treatment. This review is the first study to examine the management of SCC and to describe the neoadjuvant, adjuvant, and palliative chemoradiotherapy used to treat it. Identification of the initial stage is necessary for the management of pancreatic cancer. Patients who may be eligible for potentially curative surgery must be identified accurately. Patients with locally advanced disease or metastasis must also be identified and treated with chemotherapy or radiotherapy.
| Clinical symptoms
The literature review confirmed that the clinical presentation of SCC was similar to that of adenocarcinoma, 5 with anorexia and epigastric pain as the main symptoms. The presenting symptom was often obstructive jaundice with involvement of the pancreatic head. The tumor location was the pancreatic head in 53% of cases and the body or tail in 20% of cases. A recent epidemiologic study, which identified 214 cases during 2000-2012 using the Surveillance, Epidemiology, and End Results database, reported tumor locations of the pancreatic head in 47.7% of cases and the body or tail in 27.1% of cases. 
| Examinations
In many of the cases included in this review, diagnosis of primary SCC of the pancreas was confirmed after eliminating other possibilities, in addition to immunohistological confirmation prior to treatment. In our case, the patient received an otorhinolaryngological assessment, endoscopic examination of the gastrointestinal tract, and gynecological examination, which were all normal. Additional biopsies may be needed to confirm that the malignant cells are not of adenosquamous origin. 6 Minimally invasive methods, such as FNA, are replacing traditional surgical approaches to obtaining pancreatic tissue. 7 FNA was the method used in this case report. Abdominal CT is often the first imaging test performed when a patient's symptoms suggest a pancreatic tumor. 43 Other procedures and imaging tests used to aid diagnosis and identify metastasis include PET and pancreatic MRI.
| Histological analysis
Histological examination of the pancreatic lesion confirmed the diagnosis of SCC.
| Management of resectable tumors
It is necessary to identify the pancreatic tumor stage (resectable, locally advanced, or metastatic tumor) prior to initiating treatment. Surgery is the only effective therapy for pancreatic SCC. The quality of surgery is considered a key factor in the long-term survival of patients with pancreatic cancer. In our case, the patient had a small, localized pancreatic tumor and received a cephalic duodenopancreatectomy with transverse colectomy followed by adjuvant chemotherapy. The resectability rate of SCC in this review was 29.4%, similar to the rates reported by Makarova-Rusher et al: 10.4% for patients with SCC and 14.2% for patients with pancreatic adenocarcinoma. 2 Although significant progress has been made in the field of pancreatic resection recently, only 15%-25% of patients present with resectable disease at the time of the primary diagnosis. 44 This finding emphasizes the need for early diagnosis of, and therapeutic approaches to, pancreatic cancer.
No studies have evaluated the efficacy of neoadjuvant chemotherapy or radiotherapy in pancreas SCC. All patients with resectable pancreatic tumors received curative surgery, subsequent to neoadjuvant radiochemotherapy if the patient's general condition permitted (13.3%). Neoadjuvant or exclusive chemoradiotherapy is critical in the management of rectal, anal, and esophageal SCC. [45] [46] [47] The pancreas is a deep organ located near large vessels, and any progression of the tumor can render surgery impossible. Similar to adenocarcinoma of the pancreas, neoadjuvant treatment may be deemed unnecessary by radiochemotherapy or chemotherapy if the pancreatic SCC is resectable. 48 Only 20% of patients received chemotherapy after curative surgery. For pancreatic adenocarcinoma, there is now irrefutable evidence that adjuvant chemotherapy improves both overall and disease-free survival and that gemcitabine is the gold standard adjuvant drug. 49 For other squamous cell cancers, such as of the esophagus, adjuvant chemotherapy is not systematically recommended but may be indicated based on poor prognostic factors such as incomplete resection. 
| Management of locally advanced tumors
The majority of patients with locally advanced tumors received radiotherapy or chemoradiotherapy exclusively. This treatment has been validated for other tumor locations, including anal, rectal, and esophageal SCCs. 51 In pancreatic adenocarcinoma, neoadjuvant treatment is indicated only for patients initially staged as locally advanced/unresectable, enabling one-third of patients to receive curative surgery. 51 Since the approval of gemcitabine in 1997, more effective cytotoxic substances, such as nab-paclitaxel, and combination regimens, such as FOLFIRINOX, have become available for locally advanced tumors, possibly leading to more effective adjuvant and neoadjuvant treatment concepts for potentially resectable tumors. 8 Gemcitabine and cisplatin were the two principle drugs utilized.
| Metastatic tumors
In this review, the majority (51%) of patients with SCC had stage IV disease on initial presentation, similar to the rate of 56.4% reported by Makarova-Rusher et al. 2 The primary metastatic seeding sites were the liver and lung. The majority of metastatic patients received palliative care, which was also the preferred treatment for patients in generally poor health. The other patients were treated with a combination of cisplatin and 5-fluorouracil or gemcitabine and, less frequently, with radiochemotherapy. This approach is consistent with the recommendations for patients with pancreatic metastatic adenocarcinoma.
| Survival
Even with therapy, SCC of the pancreas is associated with a high mortality rate and overall poor prognosis. 52 This review has several limitations. The analysis was based on retrospective registers, and only case reports and case series were retrieved. Misclassification as primary pancreatic carcinoma is possible in the case of metastatic disease from another site. Consequently, there are few estimates of the degree of misdiagnosis. Despite these limitations, this review is the first study to evaluate the management of pancreatic SCC. This review reflects a global perspective, utilizing data from many countries, and can be used by medical personnel for treatment of a new case of pancreatic SCC.
| CONCLUSION
Squamous cell carcinoma of the pancreas is aggressive and rare. Clinical presentation and diagnostic approaches are similar to those for other pancreatic tumors. Surgical resection is the only curative option but is often limited by local and distant metastases. A multidisciplinary approach is needed to improve long-term survival in this still-challenging disease. Prospective international research is required to validate the management of SCC.
